Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Laurus Labs Limited (LAURUSLABS.NS)
Hyderabad, IN
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.07% | +7.71% | +16.57% | +25.70% | +29.43% | +15.56% | +115.76% | +312.17% | +164.19% | +1,232.64% | +1,232.64% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 3 | 0 |
| Sell | 3 | 0 |
| Strong Sell | 2 | -1 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+22.7% ★ Q1'26: +5.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+147.7% ★ Q1'26: +19.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+12.6% Q1'26: +33.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.1% ★ Q1'26: +21.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+12.5% ★ Q1'26: +15.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.42× Q1'26: 1.23× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 11 Rev. Ana. 10 EPS Ana. |
Mar 2027 12 Rev. Ana. 10 EPS Ana. |
Mar 2028 15 Rev. Ana. 14 EPS Ana. |
Mar 2029 6 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
19.05B
est: 20.47B (-7.0%)
|
20.56B
est: 20.67B (-0.5%)
|
22.92B
est: 22.90B (+0.1%)
|
28.32B
est: 28.18B (+0.5%)
|
48.14B
est: 46.42B (+3.7%)
|
49.36B
est: 48.48B (+1.8%)
|
60.41B
est: 60.27B (+0.2%)
|
50.41B
est: 50.54B (-0.3%)
|
55.54B
est: 54.93B (+1.1%)
|
68.85B
67.22B – 70.19B
+25.3% YoY
|
79.05B
77.21B – 82.11B
+14.8% YoY
|
91.56B
86.19B – 100.15B
+15.8% YoY
|
102.94B
102.78B – 103.11B
+12.4% YoY
|
| EBITDA |
4.08B
est: 4.96B (-17.8%)
|
4.19B
est: 2.92B (+43.4%)
|
3.75B
est: 3.33B (+12.6%)
|
5.65B
est: 2.40B (+134.8%)
|
15.50B
est: 5.24B (+195.8%)
|
14.18B
est: 5.89B (+140.7%)
|
16.06B
est: 6.74B (+138.3%)
|
7.63B
est: 11.64B (-34.5%)
|
10.34B
est: 12.80B (-19.2%)
|
15.86B
15.48B – 16.16B
+23.9% YoY
|
18.21B
17.78B – 18.91B
+14.8% YoY
|
21.09B
19.85B – 23.07B
+15.8% YoY
|
23.71B
23.67B – 23.75B
+12.4% YoY
|
| EBIT |
3.05B
est: 3.78B (-19.4%)
|
2.97B
est: 3.28B (-9.2%)
|
2.15B
est: 3.19B (-32.5%)
|
3.83B
est: 2.36B (+62.6%)
|
13.51B
est: 5.06B (+167.0%)
|
11.75B
est: 5.69B (+106.6%)
|
12.95B
est: 6.51B (+98.9%)
|
3.95B
est: 8.43B (-53.1%)
|
6.25B
est: 9.27B (-32.5%)
|
11.48B
11.21B – 11.70B
+23.9% YoY
|
13.18B
12.88B – 13.69B
+14.8% YoY
|
15.27B
14.37B – 16.70B
+15.8% YoY
|
17.17B
17.14B – 17.19B
+12.4% YoY
|
| Net Income |
1.90B
est: 1.95B (-2.3%)
|
1.68B
est: 2.04B (-17.9%)
|
937.64M
est: 1.82B (-48.5%)
|
2.55B
est: 1.15B (+121.6%)
|
9.84B
est: 3.37B (+191.6%)
|
8.28B
est: 3.79B (+118.2%)
|
7.90B
est: 4.34B (+82.1%)
|
1.61B
est: 1.48B (+8.3%)
|
3.58B
est: 3.22B (+11.2%)
|
8.89B
7.63B – 9.24B
+175.8% YoY
|
11.07B
10.59B – 12.52B
+24.6% YoY
|
13.51B
10.35B – 17.19B
+22.0% YoY
|
15.80B
14.68B – 16.89B
+17.0% YoY
|
| SGA |
2.35B
est: 2.27B (+3.4%)
|
2.70B
est: 4.92B (-45.1%)
|
3.04B
est: 4.99B (-39.1%)
|
3.55B
est: 3.55B (+0.0%)
|
4.38B
est: 9.03B (-51.5%)
|
5.04B
est: 10.16B (-50.3%)
|
6.00B
est: 11.62B (-48.4%)
|
6.53B
est: 6.83B (-4.4%)
|
7.37B
est: 7.51B (-1.9%)
|
9.30B
9.08B – 9.48B
+23.9% YoY
|
10.68B
10.43B – 11.09B
+14.8% YoY
|
12.37B
11.65B – 13.53B
+15.8% YoY
|
13.91B
13.89B – 13.93B
+12.4% YoY
|
| EPS |
4.16
est: 3.61 (+15.2%)
|
3.17
est: 3.16 (+0.3%)
|
1.77
est: 1.95 (-9.3%)
|
4.79
est: 4.69 (+2.2%)
|
18.36
est: 17.63 (+4.2%)
|
15.42
est: 15.44 (-0.1%)
|
14.69
est: 15.54 (-5.4%)
|
2.98
est: 2.75 (+8.5%)
|
6.65
est: 5.86 (+13.4%)
|
16.19
14.12 – 17.10
+176.1% YoY
|
20.80
19.60 – 23.17
+28.4% YoY
|
25.56
19.15 – 31.81
+22.9% YoY
|
29.32
27.17 – 31.27
+14.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.07% | 155.9K | 0.07% |
| 2 | Schwab Emerging Markets Equity ETF SCHE | 0.05% | 6.86M | 0.06% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.04% | 69.66M | 0.06% |
| 4 | Vanguard ESG International Stock ETF VSGX | 0.02% | 998.2K | 0.10% |
| 5 | Vanguard FTSE All-World ex-US ETF VEU | 0.01% | 12.15M | 0.04% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.01% | 75.74M | 0.05% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 4.20M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Satyanarayana Chava | Chief Executive Officer & Whole Time Director | 131M | — |
| Vantaram Venkata Ravi Kumar in Mgmt. | Chief Financial Officer & Whole-Time Director | 45M | male |
| Lakshmana Rao Venkata Chunduru | Executive Director of Quality & Executive Director | 30M | — |
| Krishna Chaitanya Chava | Executive Director of Synthesis & Executive Director | 18M | male |
| Srinivasa Rao Suryadevara | Executive Vice President of Manufacturing | — | male |
| V. R. K. Suryadevara Srinivasa Rao | President of Manufacturing and Operations | — | male |
| Nurubasha Babchand | Senior Vice President of Generics | — | male |
| Gogireddy Venkateswar Reddy | Vice President of Legal, Compliance Officer & Company Secretary | — | male |
| Narasimha Rao Chava | Executive Vice President of Human Resources | — | male |
| Chagarlamudi Sita Ramaiah | Executive Vice President of Finance | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LAURUSLABS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
